New research from Mass General Brigham guides treatment regimen for aggressive blood cancer
Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas
Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found that patients with these lymphomas had improved survival rates when treated with small molecule inhibitors as second-line therapy, followed by epigenetic modifiers as third-line therapy. Results of the study are published in the British Journal of Haematology.
“Our robust ...